RxDoctor Payments Data

Cara Ricotta, DO

Family Medicine · State College, PANPI 1275781569

Payments from drug & device makers

$986in general payments, 2019–2025

Across 57 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$207
  • Pfizer$183
  • Novo Nordisk$161
  • GSK$124
  • AstraZeneca$64
  • E.r. Squibb & Sons, L.L.C.$46
  • plus $201 from 8 others

What the payments were for

  • Food & beverage$986100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$986 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$155,761
Medicare patients
358
Services billed
1,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban196$199,859
OzempicSemaglutide170$183,124
JardianceEmpagliflozin108$123,407
XareltoRivaroxaban82$63,380
TrulicityDulaglutide38$54,622
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$49,883
TradjentaLinagliptin24$32,175
Breo ElliptaFluticasone/Vilanterol59$31,230
LinzessLinaclotide38$25,023
JanuviaSitagliptin Phosphate24$24,952
RybelsusSemaglutide11$21,224
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr43$19,880
MounjaroTirzepatide19$19,563
MyrbetriqMirabegron38$19,512
Spiriva RespimatTiotropium Bromide22$18,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$183$208,600217 claims
Novo NordiskOzempic, Rybelsus$161$204,348181 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$42$173,746154 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$124$100,993161 claims
Lilly USA, LLCTrulicity, Mounjaro$28$74,18657 claims
Johnson & JohnsonXarelto$29$63,38082 claims
AbbVieLinzess, Synthroid$207$28,172120 claims
NovartisEntresto$22$14,39316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in State College

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →